Brief: Adocia, Tonghua Dongbao Reports Positive Phase 3 Results For Ultra-Rapid Insulin In T2D
25/07/2025 07:53
July 25 (Reuters) - Adocia SA ADOC.PA: ADOCIA AND TONGHUA DONGBAO ANNOUNCE POSITIVE TOPLINE RESULTS OF PHASE 3 CLINICAL TRIAL ON ULTRA-RAPID INSULIN BIOCHAPERONE® LISPRO (THDB0206 INJECTION) IN PEOPLE WITH T2D ADOCIA SA - PHASE 3 TRIAL SHOWS THDB0206 COMPARABLE TO HUMALOG ADOCIA SA - THDB0206 INJECTION GROUP MET PRIMARY ENDPOINT Source text: ID:nBw6QWsCta Further company coverage: ADOC.PA ((( Reuters.Briefs@thomsonreuters.com );))
Recent news on Adocia SA
See all newsFrench biopharma firm Adocia H1 revenue drops on weaker feasibility study income
Brief: Adocia H1 Operating Income EUR -7.947 Million
Brief: Adocia Says Sanofi’S Exclusive Right For Partnership Agreement For Development Of M1Pram Has Expired
Brief: Adocia And Vester Finance Sign Shareholder Loan Agreement
Brief: Adocia Sees Challenges With GLP-1, Amylin & Other Metabolic Peptides